Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma

被引:28
作者
Böckmann, M
Drosten, M
Pützer, BM
机构
[1] Univ Rostock, Sch Med, Dept Vectorol & Expt Gene Therapy, D-18055 Rostock, Germany
[2] Univ Essen Gesamthsch, Sch Med, Inst Mol Biol, Ctr Canc Res Canc Therapy, Essen, Germany
关键词
targeting; cancer; phage display; medullary thyroid carcinoma; CAR; alpha v-integrin;
D O I
10.1002/jgm.648
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background Adenovirus efficiently infects a broad range of target cells, thereby preventing selective gene transfer. Moreover, several cell types and tissues including primary tumors are refractory to adenoviral infection, mainly because of low expression levels of coxsackie-adenovirus receptor (CAR). Thus, identification of cancer-selective ligands which yield gene transfer to neoplastic cells by minimizing transduction of normal cells is a key issue for successful cancer therapy. Methods We initially analyzed adenoviral receptor expression in human medullary thyroid carcinoma (MTC cells. MTC cell-specific peptides were isolated by biopanning a phage display peptide library on cultured cancer cells and on tumors in vivo and further characterized. Results We found significant differences in CAR and alphav-integrin protein levels between MTC-derived TT cells in vitro and established xenograft tumors in mice, indicating a lack of av-integrin expression on growing tumors. MTC-specific candidates were identified by performing three rounds of subtraction. Selected phages showed up to 22-fold higher binding efficiency for TT cells when compared with wild-type M13 phage or other human cell lines and tumor tissue in vivo. Homing to TT cells of the best binding phage was clearly blocked in the presence of specific peptide, whereas no phage competition was observed with an unspecific peptide. The best binding peptide mediated efficient internalization of the phage. importantly, specific binding and internalization was also mediated by the identified peptide within the adenoviral context. Conclusions Our results indicate that the identified ligand should be suitable to improve selectivity of adenoviral gene transfer to medullary thyroid tumors in vivo. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 38 条
[1]   Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [J].
Arap, W ;
Pasqualini, R ;
Ruoslahti, E .
SCIENCE, 1998, 279 (5349) :377-380
[2]   Steps toward mapping the human vasculature by phage display [J].
Arap, W ;
Kolonin, MG ;
Trepel, M ;
Lahdenranta, J ;
Cardó-Vila, M ;
Giordano, RJ ;
Mintz, PJ ;
Ardelt, PU ;
Yao, VJ ;
Vidal, CI ;
Chen, L ;
Flamm, A ;
Valtanen, H ;
Weavind, LM ;
Hicks, ME ;
Pollock, RE ;
Botz, GH ;
Bucana, CD ;
Koivunen, E ;
Cahill, D ;
Troncoso, P ;
Baggerly, KA ;
Pentz, RD ;
Do, KA ;
Logothetis, CJ ;
Pasqualini, R .
NATURE MEDICINE, 2002, 8 (02) :121-127
[3]   Targeting urothelium: Ex vivo assay standardization and selection of internalizing ligands [J].
Ardelt, PU ;
Wood, CG ;
Chen, L ;
Mintz, PJ ;
Moya, C ;
Arap, MA ;
Wright, KC ;
Pasqualini, R ;
Arap, W .
JOURNAL OF UROLOGY, 2003, 169 (04) :1535-1540
[4]  
ASAI N, 1995, MOL CELL BIOL, V15, P1613
[5]   Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries [J].
Barry, MA ;
Dower, WJ ;
Johnston, SA .
NATURE MEDICINE, 1996, 2 (03) :299-305
[6]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[7]   The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses [J].
Bergelson, JM ;
Krithivas, A ;
Celi, L ;
Droguett, G ;
Horwitz, MS ;
Wickham, T ;
Crowell, RL ;
Finberg, RW .
JOURNAL OF VIROLOGY, 1998, 72 (01) :415-419
[8]   POINT MUTATION OF THE RET PROTOONCOGENE IN THE TT HUMAN MEDULLARY-THYROID CARCINOMA CELL-LINE [J].
CARLOMAGNO, F ;
SALVATORE, D ;
SANTORO, M ;
DEFRANCISCIS, V ;
QUADRO, L ;
PANARIELLO, L ;
COLANTUONI, V ;
FUSCO, A .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 207 (03) :1022-1028
[9]   A new, therapeutic approach in medullary thyroid cancer treatment:: Inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant [J].
Drosten, M ;
Frilling, A ;
Stiewe, T ;
Pützer, BM .
SURGERY, 2002, 132 (06) :991-997
[10]   Antitumor capacity of a dominant-negative RET Proto-oncogene mutant in a medullary thyroid carcinoma model [J].
Drosten, M ;
Stiewe, T ;
Pützer, BM .
HUMAN GENE THERAPY, 2003, 14 (10) :971-982